Experimental Drug May Be Universal Cure for Kinetoplastid-Based Diseases
By LabMedica International staff writers Posted on 17 Aug 2016 |
Image: Trypanosoma sp. parasites in blood smear from a patient with African trypanosomiasis (Photo courtesy of the CDC).
An experimental drug that targets the kinetoplast proteasome found in several types of protozoan parasites shows potential for development into a universal treatment for these pathogenic microorganisms.
Chagas disease, leishmaniasis, and sleeping sickness affect some 20 million people worldwide and lead to more than 50,000 deaths annually. The diseases are caused by infection with the kinetoplastid parasites Trypanosoma cruzi, Leishmania spp., and Trypanosoma brucei spp., respectively. These parasites have similar biology and genomic sequence, suggesting that all three diseases could be cured by treatment to block the activity of a conserved parasite target. However, no such molecular targets or broad-spectrum drugs have been identified to date.
A significant advance in the search for a drug to treat kinetoplastid parasite infections was described in the August 8, 2016, online edition of the journal Nature. Investigators from several British research institutes in collaboration with the Novartis Research Foundation (San Diego, CA, USA) and the Wellcome Trust (United Kingdom) evaluated the experimental drug GNF6702, which had been discovered during a screen of more than three million compounds by the Genomics Institute of the Novartis Research Institute.
The investigators reported that GNF6702 demonstrated unprecedented in vivo efficacy by clearing parasites from mice in all three models of infection. GNF6702 inhibited the kinetoplastid proteasome through a non-competitive mechanism, did not inhibit the mammalian proteasome or growth of mammalian cells, and was well tolerated in mice.
Senior author Dr. Frantisek Supek, a biotechnology researcher at the Novartis Research Foundation, said, "We found that these parasites harbor a common weakness. We hope to exploit this weakness to discover and develop a single class of drugs for all three diseases."
Dr. Stephen Caddick, director of innovation at the Wellcome Trust, said, "These three diseases lead to more than 50,000 deaths annually, yet they receive relatively little funding for research and drug development. We hope that our early stage support for this research will provide a basis for the development of new treatments that could reduce suffering for millions of people in the poorest regions of the world."
Related Links:
Novartis Research Foundation
Wellcome Trust
Chagas disease, leishmaniasis, and sleeping sickness affect some 20 million people worldwide and lead to more than 50,000 deaths annually. The diseases are caused by infection with the kinetoplastid parasites Trypanosoma cruzi, Leishmania spp., and Trypanosoma brucei spp., respectively. These parasites have similar biology and genomic sequence, suggesting that all three diseases could be cured by treatment to block the activity of a conserved parasite target. However, no such molecular targets or broad-spectrum drugs have been identified to date.
A significant advance in the search for a drug to treat kinetoplastid parasite infections was described in the August 8, 2016, online edition of the journal Nature. Investigators from several British research institutes in collaboration with the Novartis Research Foundation (San Diego, CA, USA) and the Wellcome Trust (United Kingdom) evaluated the experimental drug GNF6702, which had been discovered during a screen of more than three million compounds by the Genomics Institute of the Novartis Research Institute.
The investigators reported that GNF6702 demonstrated unprecedented in vivo efficacy by clearing parasites from mice in all three models of infection. GNF6702 inhibited the kinetoplastid proteasome through a non-competitive mechanism, did not inhibit the mammalian proteasome or growth of mammalian cells, and was well tolerated in mice.
Senior author Dr. Frantisek Supek, a biotechnology researcher at the Novartis Research Foundation, said, "We found that these parasites harbor a common weakness. We hope to exploit this weakness to discover and develop a single class of drugs for all three diseases."
Dr. Stephen Caddick, director of innovation at the Wellcome Trust, said, "These three diseases lead to more than 50,000 deaths annually, yet they receive relatively little funding for research and drug development. We hope that our early stage support for this research will provide a basis for the development of new treatments that could reduce suffering for millions of people in the poorest regions of the world."
Related Links:
Novartis Research Foundation
Wellcome Trust
Latest BioResearch News
- Genome Analysis Predicts Likelihood of Neurodisability in Oxygen-Deprived Newborns
- Gene Panel Predicts Disease Progession for Patients with B-cell Lymphoma
- New Method Simplifies Preparation of Tumor Genomic DNA Libraries
- New Tool Developed for Diagnosis of Chronic HBV Infection
- Panel of Genetic Loci Accurately Predicts Risk of Developing Gout
- Disrupted TGFB Signaling Linked to Increased Cancer-Related Bacteria
- Gene Fusion Protein Proposed as Prostate Cancer Biomarker
- NIV Test to Diagnose and Monitor Vascular Complications in Diabetes
- Semen Exosome MicroRNA Proves Biomarker for Prostate Cancer
- Genetic Loci Link Plasma Lipid Levels to CVD Risk
- Newly Identified Gene Network Aids in Early Diagnosis of Autism Spectrum Disorder
- Link Confirmed between Living in Poverty and Developing Diseases
- Genomic Study Identifies Kidney Disease Loci in Type I Diabetes Patients
- Liquid Biopsy More Effective for Analyzing Tumor Drug Resistance Mutations
- New Liquid Biopsy Assay Reveals Host-Pathogen Interactions
- Method Developed for Enriching Trophoblast Population in Samples